HOUSTON -- Progression-free survival for 6 months (PFS6) in recurrent/progressive high-grade meningioma improved more than threefold versus historical outcomes in patients who received the CDK4/6 ...

Concarlo is harnessing decades of research and experience to clean up what precision oncology leaves behind by targeting a unique cellular pathway. They are driven by their vision of creating a world ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer. Findings from a recent clinical trial ...

Effect of small molecule Magmas inhibitor (SMMI) on human glioblastoma multiforme cell line apoptosis. The influence of FDG-PET/CT on CT-based surgical management for patients with squamous-cell ...